Pashtoon Kasi: The 1st Agnostic Study of a PARP Inhibitor
Pashtoon Kasi, Medical Director at City of Hope, shared on LinkedIn:
“Published today JCOPO, American Society of Clinical Oncology (ASCO)
The 1st agnostic study of a PARP inhibitor:
LODESTAR: Rucaparib
Need to think about variants in Homologous Recombination Repair (HRR) Genes beyond canonical BRCA PALB2.
Novel insights. Years of effort.”
Title: LODESTAR: A Single-Arm Phase II Study of Rucaparib in Solid Tumors With Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes
Authors: Sriram Anbil, Nicholas J. Seewald, E. Gabriela Chiorean, Maen Hussein, Pashtoon Murtaza Kasi, Doug E. Laux, Gary K. Schwartz, Geoffrey I. Shapiro, Kevin K. Lin, Marcia Craib, Lara Maloney, Karen McLachlan, Hanna Tukachinsky, Alexa B. Schrock, Shuoguo Wang, Ethan S. Sokol, Brennan Decker, Katherine L. Nathanson, Susan M. Domchek, Kim A. Reiss
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023